Viking Therapeutics posts stable trading day after strong capital inflow
By Redaktion aktie.com
This article was created with the help of artificial intelligence.
Key Takeaways
- Viking Therapeutics closed on August 19, 2026 at $28.70, representing a minimal gain of 0.17 percent.
- The company reported a net loss of $128.02 million for the second quarter of 2026 and completed capital measures in late July 2026.
- The lead drug VK2735, a dual GLP-1/GIP receptor agonist for obesity, is in Phase III trials.
- 23 of 24 analysts rate the stock as 'Buy' or 'Strong Buy'; the average price target is $93.60 (as of July 9, 2026).
- Market capitalization is approximately $3.8 billion with a beta of 0.61, indicating below-average volatility.
Viking Therapeutics Inc. (NASDAQ: VKTX) closed on August 19, 2026 at $28.70, representing a minimal gain of 0.17 percent compared to the previous day. The stock traded in a range between $28.50 and $29.15 during the day with a trading volume of 774,900 shares.
Capital measure completed in late July
The San Diego-based biotechnology company filed two significant capital measures in late July 2026: a capital increase and the registration of additional shares. The company reported a net loss of $128.02 million for the second quarter of 2026, representing a higher loss compared to the year-ago period.
Focus on metabolic disorders
Viking Therapeutics focuses on developing novel therapies for metabolic and endocrine disorders. Its lead product VK2735 is a dual GLP-1/GIP receptor agonist for treating obesity – a drug class currently generating significant investor and pharmaceutical industry interest. The injectable form of VK2735 is currently in Phase III trials, while an oral formulation is being tested in earlier development phases.
GLP-1/GIP receptor agonists are drugs that bind to two different receptors in the body and both lower blood sugar levels and reduce appetite. This dual mechanism of action makes them promising candidates for treating obesity and associated metabolic disorders.
Analyst ratings show optimism
Based on data from July 9, 2026, 23 analysts rate the stock as \"Buy\" or \"Strong Buy\", while only one analyst gives a neutral \"Hold\" rating. The average price target is $93.60, with a range from $83 to $101. The median of analyst estimates is $95. These ratings reflect expectations for progress in the clinical program.
Technical indicators in neutral range
The Relative Strength Index (RSI) stood at 44.99 points on August 18, 2026. An RSI is a technical indicator that shows overbought or oversold conditions of a stock – values below 30 are considered oversold, values above 70 are considered overbought. The current value suggests a neutral market condition without pronounced buying or selling momentum.
The stock's 52-week high is $43.15 and its 52-week low is $22.96. Market capitalization is approximately $3.8 billion. With a beta of 0.61, the stock shows below-average volatility compared to the overall market – a value below 1 indicates lower volatility than the market average.
Clinical pipeline as value driver
For biotech companies without approved products, valuation heavily depends on progress in clinical development. Viking Therapeutics is in the critical Phase III testing stage with VK2735, where efficacy and safety must be demonstrated in a larger patient population. Positive study results could form the basis for a regulatory filing with health authorities.
The company currently generates no revenue and reports a negative earnings per share (EPS) of -$4.66, which is typical for clinical biotech companies in this development stage. Financing comes through the capital market until potential licensing agreements or product approvals generate revenue.